ABSTRACT An azide analog, 2-[4-(4-azidobenzoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline (CP59,430), of the highly selective a1-adrenergic receptor antagonist prazosin was synthesized and its effects on rat hepatic membrane and affinity-purified a1-adrenergic receptor preparations were examined. CP59,430 behaved as a competitive antagonist before photolysis. When the membrane or purified preparations pretreated with CP59,430 were irradiated with UV While considerable progress has been made with the isolation, purification, and molecular characterization of a number of hormone and drug receptors (1-3), studies of the a-adrenergic receptor have been hampered by the lack of suitable techniques for the isolation and characterization of the minute quantities of this receptor present in most cells. In recent years, photoaffinity labels for several hormone and drug receptors have been developed and have aided greatly in the identification and biophysical characterization of these receptors (4-7). Such photoaffinity probes offer the advantage over affinity labels ofbeing completely reversible until photoactivated. Reliable affinity constants can thus be obtained, and the labels can be characterized prior to their photolysis and concomitant irreversible binding. We have previously described the development and application of an affinity matrix synthesized with an analog of the highly selective a1-adrenergic receptor antagonist prazosin, which permitted purification of the a1-adrenergic receptor (8-10). To further aid in the molecular characterization of this receptor, a specific photoaffinity label has been developed. We report here on the synthesis of this compound, 2-[4-(4-azidobenzoyl)piperazin-1-yl]-4 -amino-6, 7-dimethoxyquinazoline (CP59,430), which is also an analog of prazosin (2-[4-(2-furoyl)piperazin-1-yl]4amino-6,7-dimethoxyquinazoline), and on its characterization as a photoaffinity label for the membranebound and purified a1-adrenergic receptor.
tors by 72% . In additional studies, the photolysis-induced receptor inactivation by CP59,430 remained unchanged in the presence of the scavenger p-aminobenzoic acid. It is likely, therefore, that receptor labeling by CP59,430 occurs via a true photoaffinity mechanism. CP59,430, which specifically and irreversibly labels the a1-adrenergic receptor after photolysis, should thus be uniquely valuable for the molecular characterization of this receptor.
While considerable progress has been made with the isolation, purification, and molecular characterization of a number of hormone and drug receptors (1) (2) (3) , studies of the a-adrenergic receptor have been hampered by the lack of suitable techniques for the isolation and characterization of the minute quantities of this receptor present in most cells. In recent years, photoaffinity labels for several hormone and drug receptors have been developed and have aided greatly in the identification and biophysical characterization of these receptors (4) (5) (6) (7) . Such photoaffinity probes offer the advantage over affinity labels ofbeing completely reversible until photoactivated. Reliable affinity constants can thus be obtained, and the labels can be characterized prior to their photolysis and concomitant irreversible binding. We have previously described the development and application of an affinity matrix synthesized with an analog of the highly selective a1-adrenergic receptor antagonist prazosin, which permitted purification of the a1-adrenergic receptor (8) (9) (10) . To further aid in the molecular characterization of this receptor, a specific photoaffinity label has been developed. We report here on the synthesis of this compound, 2-[4-(4-azidobenzoyl)piperazin-1-yl]-4 -amino-6, 7-dimethoxyquinazoline (CP59,430), which is also an analog of prazosin (2-[4-(2-furoyl)piperazin-1-yl]4amino-6,7-dimethoxyquinazoline), and on its characterization as a photoaffinity label for the membranebound and purified a1-adrenergic receptor.
MATERIALS AND METHODS

Materials. [3H]
Yohimbine was purchased from New England Nuclear and p-aminobenzoic acid from Sigma. The sources of all other reagents and compounds were as described (8) .
Synthesis of CP59,430. A solution of 2-(1-piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline (838 mg, 2.90 mmol) prepared as described (11) and the N-hydroxysuccinimide ester of 4-azidobenzoic acid (12) 
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(11 mg/g wet weight of liver) was markedly enhanced. Protein concentrations were determined by the method of Lowry et al. (15) .
a1-Adrenergic receptors were purified, after solubilization of the membrane-bound receptors with digitonin, by affinity chromatography using CP57,609-agarose as described (8) . A 100-to 200-fold purification was achieved by this procedure. The specific activity of this affinity-purified preparation was 30-40 pmol/mg.
Binding Assays. Binding of the radioligands to the hepatic membranes and to the purified receptor preparations was determined as described (8) CP59 ,430 was found to interact with the membrane and purified receptor with relatively high affinity (Kd = 8.5 ± 2.4 X 10-8 M, n = 4, membrane; Kd = 6.3 + 1.5 X 10-8 M, n = 3, purified). This affinity was less than that of the parent compound, prazosin (Kd = 5.8 X 10-10 M and 1.6 x 10-9 M, respectively). However, like prazosin, CP59,430 retains al selectivity, because it competes 200-to 300-fold more potently for [3H]prazosin binding to the membrane or purified receptor preparations than does the a2-selective antagonist rauwolscine (Kd = 14 X 10-6 M and 87 X 10-6 M, respectively) ( Fig. 2) . Photolysis of CP59,430 in buffer alone did not convert it to a product of higher affinity. Scatchard (Fig. 4A) Aliquots of affinity-purified receptor preparation containing specific [3H]prazosin-(5 nM) binding activity at 0.28 pmol/ml were exposed to buffer B plus 0.1% digitonin, CP59,430, prazosin, or both drugs as indicated. The mixtures were then incubated for 90 min at 40C, and the aliquots indicated were photolyzed (h ), chromatographed on Sephadex G-50 columns (1 x 13 cm), and eluted with buffer B plus 0.1% digitonin. Specific [3Hlprazosin-(5 nM) binding activity was then assayed in identical aliquots of the void volume. Results are the means ± SEMs for two studies determined in triplicate. *P < 0.01 versus aliquot 1. Photoinactivation by CP59,430 of affinity-purified a1-adrenergic receptors is shown in Table 2 . Aliquots of the purified preparation were exposed to CP59,430 (1 ,M) for 90 min, photolyzed for 15 min, and then chromatographed on a Sephadex G-50 column. Subsequent measurements of specific [3H]prazosin binding in identical aliquots of the void volume revealed a 67% loss of receptor-binding sites compared to the purified receptor preparation treated in an identical fashion with CP59,430 but without photolysis. Moreover, preincubation with prazosin (10 ,M) completely protected the purified receptors from photoinactivation by CP59,430, whereas no loss of receptor-binding activity was observed in the aliquot treated with buffer alone or in that photolyzed after preincubation with prazosin.
To investigate the mechanism of photoaffinity labeling by CP59,430, the effect of the scavenger p-aminobenzoic acid on CP59,430-induced inactivation of affinity-purified receptorbinding sites was additionally studied, as shown in Table 3 . Aliquots of the purified preparation were exposed to CP59,430 (1 ,uM), p-aminobenzoic acid (10 mM), or both agents for 90 min, photolyzed for 15 min, and then chromatographed on a Sephadex G-50 column, as described for the studies shown in Table  2 (Figs. 2 and   3 ). The affinity of CP59,430 determined in these studies is less than that of the parent compound, prazosin, but 200-to 300- fold greater than that of the a2-selective antagonist rauwolscine Biochemistry: Hess et al. (Fig. 2) (21) or photoinactivation (22) of some of the CP59,430 compound may also have occurred during the photolysis procedure. Nevertheless, the extent of receptor inactivation produced by CP59,430 compares favorably with that observed with other photoaffinity labels, some of which have been estimated to label only 1-2% of the total number of receptors (23) .
The possibility that CP59,430 reacts with buffer to generate a species of much higher affinity that would mimic an irreversible antagonist, similar to that described by Schmelck et aL (24), Erez et al. (25) , and Kenakin and Black (26) , can be eliminated by the experiments described in Fig. 2 . Thus, the affinity of CP59,430 photolyzed in buffer alone was unchanged from that observed with the native ligand. Moreover, photoinactivation of the receptor-binding sites by CP59,430 could not be reversed by extensive dialysis or chromatography. After photolysis, CP59,430 could be detected in the membranes by radioimmunoassay despite heat inactivation of the binding sites and extensive washing.
Studies with the scavenger p-aminobenzoic acid (Table 3) suggest that CP59,430 labels al-adrenergic receptor sites by a true photoaffinity labeling reaction (27) , because the photoinactivation by CP59,430 was unaltered by p-aminobenzoic acid. This mechanism contrasts with that proposed for "pseudo" (8) (9) (10) , and a radiolabeled photoaffinity ligand may provide an additional tool for its isolation and for the characterization of its biophysical properties in solution.
